149 related articles for article (PubMed ID: 19443414)
1. Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.
Vici P; Giotta F; DI Lauro L; Brandi M; Gebbia V; Foggi P; Lorusso V; Vitucci C; Sergi D; Fattoruso SI; Giannarelli D; Viola G; Corsetti S; Colucci G; Lopez M
Anticancer Res; 2009 May; 29(5):1841-5. PubMed ID: 19443414
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Kouroussis Ch; Papakotoulas P; Kalbakis K; Tryfonidis K; Vardakis N; Poppis E; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 May; 69(5):1345-52. PubMed ID: 22349809
[TBL] [Abstract][Full Text] [Related]
3. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
5. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
Brandi M; Vici P; Lopez M; Valerio MR; Giotta F; Gebbia N; Schittulli F; Colucci G;
Semin Oncol; 2004 Apr; 31(2 Suppl 5):13-9. PubMed ID: 15199527
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
7. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
Morabito A; Filippelli G; Palmeri S; Cascinu S; Ferraù F; Zagonel V; Gattuso D; Catalano V; Capaccetti B; Franciosi V; Accurso V; Scinto F; Gasparini G
Breast Cancer Res Treat; 2003 Mar; 78(1):29-36. PubMed ID: 12611454
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
Vici P; Di Lauro L; Sergi D; Foggi P; Viola G; Mottolese M; Giotta F; Fattoruso SI; Corsetti S; Giannarelli D; Botti C; Lopez M
Oncology; 2008; 75(3-4):175-81. PubMed ID: 18841031
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Pelegrí A; Calvo L; Antón A; Mayordomo JI; Florián J; Vásquez S; Arcusa A; Martín-Richard M; Bayo JL; Carrasco E; Virizuela J;
Clin Breast Cancer; 2005 Dec; 6(5):433-8. PubMed ID: 16381627
[TBL] [Abstract][Full Text] [Related]
10. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
Pelegrí A; Calvo L; Mayordomo JI; Florián J; Vázquez S; Arcusa A; Martn-Richard M; Bayo JL; Virizuela J; Carrasco E; Antón A;
Semin Oncol; 2004 Apr; 31(2 Suppl 5):20-4. PubMed ID: 15199528
[TBL] [Abstract][Full Text] [Related]
12. Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study.
Riccardi A; Brugnatelli S; Danova M; Giordano M; Pugliese P; Luchena G; Grasso D; Trotti G; Bertè R; Pansini G; Tinelli C
Tumori; 2006; 92(1):6-12. PubMed ID: 16683377
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
16. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
Schmid P; Heilmann V; Schulz CO; Dieing A; Lehenbauer-Dehm S; Jehn C; Sezer O; Possinger K; Flath B
J Cancer Res Clin Oncol; 2005 Sep; 131(9):568-74. PubMed ID: 16044345
[TBL] [Abstract][Full Text] [Related]
18. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Frasci G; Comella P; D'Aiuto G; Thomas R; Capasso I; Elmo M; Botti G; Cortino GR; Lapenta L; De Rosa V; Vallone P; Petrillo A; Comella G
Ann Oncol; 2000 Mar; 11(3):367-71. PubMed ID: 10811508
[TBL] [Abstract][Full Text] [Related]
19. [Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Semiglazova TIu; Filatova LV; Gershanovich ML
Vopr Onkol; 2005; 51(1):66-70. PubMed ID: 15909810
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
